Formed in 2014 by ACPHS President Greg Dewey, the President's Advisory Council (PAC) is comprised of leaders in the corporate, academic, and not-for-profit sectors.
The Council's overarching directive is to offer insights into how educational institutions should respond to long term trends in the health science and health care industries. The group meets twice per year.
Below is a current list of PAC members and their accompanying bios. To learn more about the Council and its activities, please read the press releases on the sidebar of this page.
Dr. Robert A. Blum has over 28 years successfully operating research programs to effectively research new medications in their early stages of drug development, writing and conducting clinical protocols, and leading a team of medical and supportive personnel in every aspect of running a research-wide program. Dr. Blum co-founded Buffalo Clinical Research Center, LLC (BCRC) in 2001. BCRC is a state-of-art Phase I research facility assisting pharmaceutical companies with early phase drug development. Dr. Blum received his B.S. in Pharmacy from Albany College of Pharmacy in 1983, where he then proceeded to get his Pharm.D. degree from the Medical University of South Carolina in 1985. He completed a Clinical Pharmacy Residency in 1986, followed by a fellowship in Pharmacokinetics in 1987. This experience took him to Buffalo, NY where ascended to the position of Director of Clinical Pharmacology Research at the Clinical Pharmacokinetics Laboratory of Millard Fillmore Hospital. Here he implemented a Phase I research program that grew from 6 beds to 34 beds and was responsible for the procurement, conduct, safety, scientific merit, and regulatory standards of all studies performed. He subsequently worked in Phase I clinical pharmacology research for the next 13 years and then started his own Phase I research company, Buffalo Clinical Research Center, LLC in 2001. The primary research focus of BCRC include “first-time-in-man” safety, tolerability and pharmacokinetic/pharmacodynamic studies, bioavailability/bioequivalence, drug interaction, gender-and food-effect studies. Dr. Blum has acted as Principal Investigator on 250 clinical pharmacology protocols, sub-investigator on 86 protocols, published 63 manuscripts in peer-reviewed scientific journals and presented 45 abstracts at peer-reviewed scientific meetings.
Dr. Bonafede is the Director of the Outcomes Research group of Truven Health Analytics (formerly Thomson Reuters Healthcare). He has significant experience in healthcare research, education, and consulting. Before joining Truven Health, Dr. Bonafede served on the faculty at Albany College of Pharmacy and Health Sciences, where he taught courses covering research and statistical methods, total quality management, and evidence-based medicine. He also helped to design and launch M.S. programs in pharmacy administration and health outcomes research. Dr. Bonafede has conducted and provided training in qualitative research methods and survey design. He also has private consulting experience in survey design, retrospective data analysis, and study presentation. He holds a Ph.D. in health services research and policy and a master’s degree in public health, both from the University of Rochester.
Dr. Carpenter is the Senior Director and Head of Clinical Research and Development at Dart Neuroscience (DNS), a San Diego-based pharmaceutical company focused on the development of novel therapeutic agents to improve human cognition and memory. Prior to joining DNS, David held senior leadership roles in the Neuroscience Drug Discovery Group and in the Neuroscience Medicines Development Center at GlaxoSmithKline Pharmaceuticals, and in the CNS Drug Development Group at Sanofi Pharmaceuticals, both in the Philadelphia area. In those roles he was responsible for the clinical development of a variety of investigational neurotherapeutic agents, in both adult as well as pediatric populations, and spanning both early (Phases 1-2) as well as late phase (Phases 3-4) development efforts. During his more than 30 years in the industry, he has been involved in the development of eight drug products to date which have successfully gained regulatory approval for marketing. David is a Registered Pharmacist, and holds a B.Sc. degree in Pharmacy from Albany College of Pharmacy and Health Sciences (class of 1981), an M.Sc. degree in Psychology/Neuroscience from Rensselaer Polytechnic Institute (Troy, NY), and a Doctor of Pharmacy (Pharm.D.) degree from the Philadelphia College of Pharmacy (now University of the Sciences). He is an active member of the College of Psychiatric and Neurologic Pharmacists (CPNP), the American Society of Clinical Pharmacology and Therapeutics (ASCPT), the American Society for Clinical Psychopharmacology (ASCP), the International Society for CNS Clinical Trials and Methodology (ISCTM), and the American Pharmaceutical Association (APhA).
Christopher Conway is Senior Vice President, Discovery and Development, at Albany Molecular Research, Inc. Mr. Conway joined AMRI in 2008 as a Business Development Manager on AMRI’s U.S. discovery team. He was promoted to Senior Director of the North America Discovery market in 2010 and then to Vice President of Business Development in 2012 leading an international team of business development managers in North America and Europe. Prior to joining AMRI, Chris held sales and leadership positions of increasing responsibility at Johnson and Johnson and completed J&J’s Sales Leadership Development Program. Chris’ strong track record in Sales and Marketing stems from the leadership and development of numerous high-profile deals with large pharmaceutical, biotechnology, non-profit, academic, agricultural, and government organizations throughout the world. Chris also led in the development of AMRI’s industry-leading insourcing model. This innovative model supports drug discovery, development, and manufacturing for pharmaceutical and biotechnology companies within their own facilities. Chris currently sits on the Siena College Board of Associate Trustees and has been involved with several volunteer boards including the American Cancer Society’s Corporate Council and the American Cancer Society’s Coaches vs. Cancer initiative. In addition, Chris has worked closely with the national Alzheimer’s Association, as well as the Cure Huntington’s Disease Initiative and was previously involved as a member of the Albany Epilepsy Foundation Advocacy Board.
As the Vice President, U.S. Medical Affairs at Incyte Corporation, Dr. Cordaro is responsible for leading Medical Affairs Functions including the Medical Science Liaison Team, Publications/Scientific Communications, Health Outcomes Research, and Medical Information Services. He is also responsible for developing and leading the departmental medical strategy and tactical plan implementation. Prior to joining Incyte, Joe was Executive Director, Development Brand Leader at AstraZeneca where he was the leader of U.S. Medical Teams and was accountable for developing brand medical strategy, the medical plan, integration of all pertinent projects into the brand plan, and execution through a cross-functional team. Prior to this, he held the position of Senior Therapeutic Brand Leader, Oncology in Medical Affairs at AstraZeneca, responsible for leading the Oncology Medical Liaison Team, leading the medical affairs core strategy team, and providing brand team support for marketed and late stage pipeline products. Joe previously held positions at Roche Pharmaceuticals most recently as Director Oncology, Scientific Field Operations in Medical Affairs responsible for leading and managing a team of Oncology Medical Liaisons supporting in-line oncology products and pipeline development products. Prior to this he held positions as Associate Director of the Oncology Clinical Liaison Team and Oncology Clinical Liaison. Prior to joining Roche, Joe was at Novartis Pharmaceuticals Corporation as Scientific Officer and Associate Director in the Oncology Business Unit at Novartis Pharmaceuticals Corporation supporting in-line products and development pipeline projects. Prior to this, Joe was an International Project Coordinator for global oncology development products in Global Project Management at Sandoz Pharma, Ltd. Dr. Cordaro received his Bachelor of Science degree in Pharmacy from Albany College of Pharmacy and Health Sciences and his Doctor of Pharmacy degree from the State University of New York at Buffalo School of Pharmacy. He completed a two-year post-doctoral Industrial Clinical Pharmacy Practice Fellowship at Sandoz Pharmaceuticals Corporation and Rutgers University College of Pharmacy where he was Chief Fellow and an Adjunct Faculty member in the Department of Pharmacy Practice. This fellowship focused on oncology and immunology clinical research and development and pharmacoeconomics. Dr. Cordaro received an Executive Pharmaceutical Marketing M.B.A. at St. Joseph’s University in Philadelphia, PA. Dr. Cordaro has over 20 years of experience in senior medical affairs leadership, field medical team management, clinical development, scientific communications, medical information systems, as well as a proven track record for enabling impactful and sustainable strategic and tactical plans for Medical Affairs.
Dr. Dadas received his Doctor of Pharmacy degree from Albany College of Pharmacy and Health Sciences in 2001. During this time in Albany, Dr. Dadas also worked at the Stratton VA Medical Center where he practiced clinical pharmacy and pharmaceutical distribution for four years. After his training at ACPHS, he completed a fellowship in U.S. Clinical Research working in the Critical Care Division of Eli Lilly and Company. As part of his fellowship, he served as Adjunct Assistant Professor at Butler University Pharmacy School, lecturing on research and regulatory topics for a course titled “Clinical Drug Development - A Regulatory View." Dr. Dadas joined Allergan, Inc. in May of 2002 and has held leadership roles as Director of Medical Affairs Operations, Director of Neurosciences Medical Liaisons, Interim Medical Director for Urology, and currently as the National Director for the Urology Medical Liaison Team. Allergan is a multi-specialty pharmaceutical company based in Irvine, CA with a $50 billion market capitalization . Allergan focuses on drug discovery, development, and commercialization in the areas of biologics, devices, small molecules and over the counter products. Dr. Dadas’ contributions range across therapeutic areas and products. His work fully integrates medical communications from many internal and external stakeholders, driving corporate research strategy and scientific direction. He has served as a key contributor and leader for Global Medical Affairs strategy and product launches. He has been responsible for design and implementing Phase II through Phase IV clinical research studies. He manages a team of scientists who establish and maintain professional relationships with clinical opinion leaders and clinical research sites. Dr. Dadas serves on numerous sub-teams and corporate councils where decisions are made in the areas of medical communications. He has received two U.S. patents for novel methods of treating diseases where there is a large unmet medical need (U.S. patent # 7,897,147 and 8,685,414) and has additional patents pending.
Tanya Dumrongmanee has a decade of experience bringing operational efficiencies to industries such as e-commerce, higher education, information technology, and manufacturing. She has led cross-functional and global teams at venture-backed startups and highly-matrixed organizations. Her past projects include ERP system implementation, supply chain management process development, and Series C funding. Tanya studied entrepreneurship at Babson College where she earned her Master of Business Administration in 2010. She currently works in product engineering at EMC Corporation and has been with the Fortune 500 company since 2011. She grew up in Los Angeles and now resides in New England.
Mr. Edwards is the Senior Vice President, Mail Service Operations for OptumRx. In this capacity, his primary responsibilities include leading all Mail Service activities, including traditional mail service and all mail fulfillment operations at OptumRx sites, including Specialty Pharmacy fulfillment and the Personal Care program, Pharmacy Practice, and Business Innovation and Operations Support (BIOS) teams. Clayton oversees a team of more than 3,000 employees in five locations across the country that dispenses more than 30 million prescriptions annually.
Clayton has extensive leadership experience in pharmacy and pharmacy benefit management (PBM) settings. He served as senior vice president, Chief Pharmacy Officer with Sanari and as the president of Rhema Healthcare Consulting, specializing in all aspects of PBM management, pharmacy fulfillment and health care marketing. He previously served as the executive vice president, Clinical and Pharmacy Operations for Liberty Medical, a leading direct-to-consumer provider of diabetes testing supplies and prescriptions. In addition, Clayton served in a variety of clinical pharmacy and health management roles with Medco, most notably in the development and management of disease specific programs and the formation of the Medicare Part D business unit, accountable for the State of New Jersey business and the enterprise interactions with the Centers for Medicare & Medicaid Services (CMS). Clayton received a Bachelor of Science degree in pharmacy from Albany College of Pharmacy and Health Sciences and his Master of Business Administration (MBA) in health administration and marketing from Saint Joseph’s University. He is a member of the Academy of Managed Care Pharmacy (AMCP) and the American Pharmacists Association (APhA) and holds a professional certificate from the Academy for Healthcare Management (AHM).
Shahrokh (Seve) focuses his law practice on patent and trademark law, with particular emphasis on patent and trademark filings, prosecution, and client counseling. Seve takes into account clients’ business goals to provide a full range of counseling, patent and trademark filings and prosecutions, and agreement services to his clients. He has more than nine years of experience managing patent portfolios and represents many U.S. based and foreign based clients with interests in new and emerging technologies. His clients range from university faculty and researchers, to start-up companies developing new technologies, and larger established corporations. Seve is the Managing Partner of Albany-based FALATI Intellectual Property Law & Management Consultancy firm, leading a group of seven experienced Intellectual Property law attorneys. Seve is admitted to practice law in New York and Massachusetts, before the United States District Court for the District of Massachusetts, and as a registered patent attorney before the United States Patent & Trademark Office. Prior to entering the legal profession, Seve graduated with a B.Sc. with Honours and a Ph.D., both in Pharmacology, while studying in the United Kingdom, and completed a three year Postdoctoral Fellowship at Harvard Medical School / Beth Israel Deaconess Medical Center.
Helen is Executive Vice President, Global Strategic Development, LumiraDx, USA, Inc. responsible for building international collaborations and global best healthcare technology solution portfolios.
Before joining LumiraDx, USA, Inc. she was in HIMSS senior leadership (Health Information Management Systems Society) and previously to that excelled in three Fortune 500 companies. She has an extensive healthcare and healthcare technology background, developed nationally recognized client loyalty programs, best practice programs and various governmental healthcare reform initiatives, both nationally and on the international level. She has achieved Health Information and Management System Society (HIMSS) fellow status and secured HIMSS designation of Certified Professional in Health Information Management System (CPHIMS). She serves on committees and Boards for various organizations such as HIMSS, CHIME (College of Healthcare Information Management Executives), The Sullivan Institute for Healthcare Innovation and WEDI, State University of New York’s Global Institute for Health and Human Rights, the State University of New York’s Center for Global Health. She is currently serving on the committee for the strategic planning initiatives for the University at Albany SUNY Center for Global Strategic Health. She serves as the HIMSS National Liaison for the State of New York. She has secured service awards and various career recognitions and has published and lectured extensively in healthcare and healthcare technology.
She authors a quarterly healthcare technology column educating clinicians about healthcare technology solutions and processes. She holds academic appointments at University of Maryland and the Sage Colleges, New York. She has a Baccalaureate in Science, a Doctorate of Pharmacy, and trained in the Harvard teaching hospitals, Boston, MA. She completed a drug information research fellowship, has an MBA in healthcare administration,is a Certified Six Sigma Black Belt and Certified Six Sigma Lean Sensei. She was named by Health Data Management’s as one of “The Most Powerful Women in Healthcare IT Thought Leaders 2016”. Helen is passionate about giving back and mentoring others in the healthcare industry. She authors the column in US Pharmacist called “TechRx” educating pharmacists on the nuances of healthcare IT and various technology solutions.
She volunteers her time and skills and supports fundraising efforts for various organizations supporting the environment and humanity.
Tom Garcia is a Research Fellow in Global CMC, Pfizer Inc., Groton, Connecticut. He received a B.S. in Pharmacy from Albany College of Pharmacy in 1983, and a Ph.D. in Industrial and Physical Pharmacy from Purdue University in 1989. Tom has over 26 years of experience in the pharmaceutical industry. He spent the first 14 years doing process development and technology transfer, where his primary interests were powder mixing, blend sampling, and the use of statistical techniques to optimization and assess process capability and robustness. He joined Pfizer’s Global Chemistry and Manufacturing Controls (regulatory) group in 2003. He is a member of the GCMC Advisory Office, working with cross-functional teams to define development and regulatory strategies that generate the data required for the preparation and submission of global NDAs/MAAs, as well as responses to regulatory queries and observations. Tom is also a member of Pfizer’s License and Management team where he assesses the quality and value of external opportunities. He was a member of the SUPAC IR Industry Training Committee, served as Chair of the PQRI Blend Uniformity Working Group, and was a member of the MIT Regulatory Sub-Team for continuous manufacturing (2014). Tom has been active in ISPE, serving on various Groups (BUCU Group (leader), ISPE Process Capability Statistics Group, Control Strategy Task Team), and is a member of the Rutgers C-SOPS Continuous Manufacturing Regulatory Working Group. He is an Adjunct Associate Professor in the Department of Pharmaceutical Sciences at Albany College of Pharmacy and Health Sciences, and held a similar position at Campbell University from 1996 – 2000.
Marylee Grosso, RPh is managing partner of HealthCare Consulting Service (HCS), an independent consulting company that addresses the challenges faced by post-acute care providers, vendors and professional organizations in a rapidly changing regulatory and reimbursement environment. A healthcare executive, with over 30 years of professional clinical management experience, Marylee most recently was Corporate Senior Director of Clinical Operations for Genesis Healthcare, overseeing the clinical pharmacy practice standards of the Nursing and Medical Affairs Departments in over 510 centers nationally. In this capacity, Marylee was responsible for Clinical Pharmacy Programs with focused attention on the development of a comprehensive medication reconciliation process for patients admitted to Genesis PowerBack Centers. Additionally she was the clinical liaison with the Genesis pharmacy providers and managed the regulatory compliance monitoring and reporting processes for Genesis. Prior to joining Genesis, Marylee was a clinical pharmacist specialist with the VA Medical Center in Syracuse, New York responsible for clinical pharmacy program management. She holds a bachelor of science degree in pharmacy from Albany College of Pharmacy and Health Sciences and is a member of the national and Maryland Chapters of the American Society of Consultant Pharmacists (ASCP) and the American Healthcare Association (AHCA). She has been a guest speaker for ASHP/INS; the District of Columbia and Delaware Healthcare Associations, the American Society of Consultant Pharmacists LTC Marketplace, and the ASCP and AHCA national meetings. She has served on the AMDA Immunization Work Group, the ASCP Pharmacy Quality Alliance’s workgroups for MTM (Medication Therapy Management) and Medication Error Management and the Committee for Innovations, MDASCP CRISP Workgroup and the AHCA Regulatory Affairs, Adverse Events and Clinical Practice Committees.
Frank Grosso has 35 years of Long Term Care (LTC) Pharmacy experience and is currently Executive Director and CEO of the American Society of Consultant Pharmacists. Prior to his current position, Frank was Vice President of Pharmacy Services for Genesis Healthcare, a Long Term Care Provider, with corporate headquarters in Kennett Square, PA. His responsibilities included oversight of the operational and contracted pharmacy services for 411 Nursing Centers and Assisted Living Communities owned and managed by Genesis. Frank’s experience began with Consultant Pharmacy and includes LTC Pharmacy Sales and Operations Management and serving as Senior Vice President of Pharmacy Operations for NeighborCare Pharmacy for 14 years. In addition to ASCP (1980) and AHCA (2006) memberships, Frank has been an active participant in several AHCA and ASCP Committees including Pharmacy Advisory Group, DEA Taskforce, and Policy and Advocacy.
As vice president of National Pharmacy Programs and Services at Kaiser Permanente, David Kvancz oversees Pharmacy operations across the Program to ensure it is positioned to optimize performance and delivery of quality, service, affordability, and technology. Kvancz collaborates with key leaders and physicians to find new and effective ways to integrate clinical pharmacists into the care delivery and chronic disease management to achieve systemwide improvements in patient care outcomes. A nationally-known leader in clinical pharmacy operations, Kvancz came to Kaiser Permanente from The Cleveland Clinic. He began his career there in 1997 as director of pharmacy and in 2003 was promoted to chief pharmacy officer. In that position, he directed the operation of all pharmaceutical care services throughout the system, including integrating pharmacy services into clinical practices and partnering closely with physicians. Kvancz previously served as the associate director of clinical pharmacy services at the University of Texas Medical Branch at Galveston from 1994-1997, where he directed inpatient and ambulatory pharmaceutical care practices. From 1982-1994, he served as assistant director of pharmacy at Tucson Medical Center’s inpatient and ambulatory pharmacy operations and practice models including pharmacy information and automation support services. Kvancz has served as a member and chairman of the American Society of Health-System Pharmacists' (ASHP) Practice Managers Section, as a member and co-chair of the Organizational Affairs and Professional Affairs Councils, and as a member of the ASHP and Georgetown University Center for Health System Pharmacy Leadership Development Advisory Committee. He was named a Fellow of ASHP in 1990. He earned a bachelor's degree in pharmacy from Albany College of Pharmacy and Health Sciences and a master's degree in hospital pharmacy from Ohio State University. He completed his ASHP-accredited residency at Mount Carmel Medical Center in Columbus, Ohio.
As the Executive Director for the Alfred E. Mann Institute for Biomedical Engineering at the University of Southern California (AMI-USC), Dr. Lasch brings more than 25 years of experience in science and technology development and evaluation in the fields of biomedical instruments and systems, biotechnology, chemistry, and materials science. He is a Research Professor of Biomedical Engineering in the Viterbi School of Engineering and holds a courtesy appointment as a Professor of Clinical Entrepreneurship in the Greif Center of the Marshall School of Business at USC. Prior to joining AMI-USC, he served as a Managing Director of Convergent Ventures (CV), an early stage life sciences venture investment and development company. He has served as chairman or member of the boards of directors and CEO of several CV portfolio companies. From 2002-2007, he was on the board of directors of Precision Dynamics Corporation, a privately held healthcare products company, and he currently serves as vice chairman of the board of directors of the Southern California Biomedical Council. Dr. Lasch has held leadership positions at Materia, a materials science company spun out of Caltech, where he served as founding President and CEO, and Cyrano Sciences, a Caltech spin-out based on chemical sensor technology. Previously, he served as vice president of technology development for The Scripps Research Institute, the largest not-for-profit biomedical research institute in the United States and was director of research, biotechnology, for PPG Industries. He has served on the faculty of the UCLA Anderson School of Management, in the FEMBA GAP program and for two years as the Director of the EMBA Field Study Program. He received his B.S. in Biological Science from the University of Texas at El Paso and his Ph.D. in Chemistry from the University of Texas at Austin. Dr. Lasch is also a Fellow of the American Institute for Medical and Biological Engineering. He is co-author of Seed-Stage Venture Investing: An Insider’s Guide to Start-Ups for Scientists, Engineers, and Investors.
John is the Area Healthcare Supervisor for Upstate and Western NY for the Walgreens Co. He is responsible for executing regional healthcare strategies that integrate all Walgreens healthcare offerings. He advises on pharmacy strategy, engages and empowers others, leads change, and drives results using management principles, employee development, and relationship building.
John received his B.S. in pharmacy from Albany College of Pharmacy and Health Sciences in 2003 where he served as president of his class.
In September 2014, Mr. Marraffa was appointed to the New York State Board of Pharmacy. He serves on the National Association of Boards of Pharmacy Task Force on the Regulation of Pharmacist Care Services, where he is responsible for reviewing existing state laws and regulations pertaining to the provision of pharmacist care outside of the traditional pharmacy setting. The task force reviews and recommends revisions to the NABP Model Act to assist other boards of pharmacy.
In April 2014, Governor Cuomo’s office appointed Mr. Marraffa to the New York State Medicaid Pharmacy Advisory Committee. On this committee he provides expertise related to developing and maintaining Medicaid policies that improve patient healthcare outcomes while supporting the practice of Community Pharmacy.
John serves as an adjunct experiential preceptor for Albany College of Pharmacy and Health Sciences and Massachusetts College of Pharmacy and Health Sciences University. He is an active member of the ACPHS Professionalism Task Force, Experiential Education Advisory Panel, and was President of the ACPHS Alumni Council from 2008 - 2011.
As an involved community member, John has served on the American Cancer Society’s Relay for Life Planning Committee and received the Shining Star Award in 2011 for exemplary service to the organization.
John and his wife Lauren have two sons, Nico and JJ, and a boxer dog Roxy. They reside in Fayetteville, NY.
Stephen is passionate about the development of medical products, technologies, and services that address unmet medical needs. He has had the good fortune to participate as an active executive, investor, and board member to more than two dozen companies in the industry. He has contributed to the development of numerous medical therapies and products across many areas of medicine. His scientific contributions and patents include delivery of drugs to the eye, medical devices for the treatment of tinnitus, allergy vaccines, and diagnostic tests for cervical cancer. For the past several years, the advancement of mental health and substance abuse treatment has been part of these pursuits – in both the healthcare delivery aspects and through development supportive mobile health applications. Dr. McCormack currently serves as Chairman of the Board of Directors and Chief Executive Officer of Visus Technology. Visus is advancing mobile accessibility technology through the development cloud-based computer vision solutions for the elderly and visually impaired communities. Other companies that he co-founded and operated include: AlleCure, MannKind, NeuroSystec, CytoMx, Cynvenio, American Optical Services and Exela Hearing Services. He lived in Europe for four years and was a Managing Director at Global Life Science Ventures in Zug, Switzerland and the Chief Executive Officer of Intelligent Medical Implants in Bonn, Germany. He has previously held academic positions at Georgetown University Medical Center, Rockefeller University, George Mason University, and the UMMC and was part of the founding senior management at the Keck Graduate Institute. Dr. McCormack received his Ph.D. in the Interdepartmental Biomolecular Science and Engineering program from University of California, Santa Barbara. He obtained a bachelor’s degree in biology from the College of the Holy Cross in Worcester, MA.
As the Vice President of U.S. Metabolic Marketing, David leads the marketing organization for the BI-Lilly Diabetes Alliance. This portfolio includes two products currently on the market and six more in Phase III. David concurrently managed the Pradaxa and mature brands business for almost a year prior to the role being split in two which allowed him to focus completely on the Diabetes Alliance. Prior to his current role, David spent 2 1/2 years with responsibility for all U.S. Pipeline Marketing activities from Discovery to Phase III across all therapeutic areas at Boehringer Ingelheim. Prior to joining Boehringer, David spent five years at J&J with four of them having a board position at Ortho McNeil, a J&J company. While at J&J he was responsible for their Pain Franchise which included Duragesic, Ultracet, and Ultram ER and then the Institutional Franchise which included the launch preparation for two new antibiotics as well as the existing pain and anti-infective business. Prior to J&J, David spent 10 years at Bristol Myers Squibb starting out in field based medicine progressing through strategic and in-line marketing with therapeutic experience in diabetes, schizophrenia, hyperlipidemia, hypertension, depression, and dermatology. David spent two years in the U.K. running the Primary care marketing business for BMS. David received his B.S. and Doctor of Pharmacy degree from Philadelphia College of Pharmacy and Sciences (now University of the Sciences).
Dr. Pickworth is a pharmacologist with more than 30 years of preclinical and clinical experience. He received a B.S. (pharmacy) degree from Albany College of Pharmacy and Health Sciences (1969) and a Ph.D. (pharmacology) from the University of Tennessee (1974). He was with NIH for nearly 30 years from a post-doc position to a tenured staff scientist at the National Institute on Drug Abuse. For the past ten years he has directed clinical research on tobacco and nicotine for Battelle as a Research Leader. He has served as a principal investigator throughout his career. He has published more than 100 peer review papers, book chapters, and technical reports. Dr. Pickworth has worked with numerous collaborators, including NIH colleagues, academic and health care institutions, private industry, and national and international scientific and regulatory agencies. Wallace is still active in pharmacy, holding licenses in two states, working part-time in hospital pharmacy, and serving as an adjunct faculty at two colleges of pharmacy. His current research centers around the delivery of toxicants from tobacco products including oral tobacco, cigarettes, cigars, and e-cigarettes.
Dr. Triller is Vice President of Network Transformation at MVP Healthcare in Schenectady, New York. In this capacity he leads MVP efforts in engaging providers and health systems in value-based purchasing agreements that improve patient outcomes by incentivizing high quality, high efficiency services across care settings. Prior to joining MVP in 2015 Dr. Triller was a Senior Project Director for IPRO, the Centers for Medicare and Medicaid Services (CMS)-designated Quality Improvement Organization (QIO) for New York State where he led multiple drug safety and quality improvement initiatives at the local, state, and national levels. He assembled and led the NYS Anticoagulation Coalition, a multidisciplinary group of over 160 clinicians and healthcare professionals collaborating to enhance the quality and safety of anticoagulant (AC) therapy. He also created and led similar Coalitions focusing on hypoglycemia avoidance, appropriate opioid use, and hypertension control.
Dr. Triller has contributed to several national efforts to develop, test, and implement drug-related quality measures and to promote quality improvement across the pharmacy community. He served as a member of the Technical Expert Panel (TEP) for the CMS medication quality measures development and management program led by Florida Medical Quality Assurance, Inc. (FMQAI) and is a member of the Medical and Science Advisory Board for the National Blood Clot Alliance. He also contributes to medication quality measure TEPs for the Pharmacy Quality Alliance (PQA) and the American Society of Health-System Pharmacists (ASHP). He has served as president of the NYS Chapter of the American College of Clinical Pharmacy (ACCP) and is past chair of the NY Pharmacy Conference.
Dr. Triller received both his B.S. and Pharm.D. degrees from Albany College of Pharmacy and Health Sciences (ACPHS). He completed a post-doctoral fellowship in drug safety at ACPHS, and has led numerous funded studies and peer-reviewed publications on the topics of drug safety and quality improvement throughout his 25+ year career in pharmacy. He holds an adjunct clinical faculty appointment at the college, and is an active author, speaker, and advocate for drug safety topics.
Mr. Edward A. Ullmann, brings leadership, experience and skills as an executive manager with a unique background in both private and public sectors of the health care and wellness industries. He has developed more than 30 start-up companies, and for 16 years served as the Founder, Chairman, President, and Chief Executive Officer of a publicly-traded New York-based health management company (Wellcare). Wellcare developed and managed six operating HMOs. Mr. Ullmann is a licensed pharmacist with retail experience as a Pharmacy District Manager (PDM) and operator of independent pharmacies. Mr. Ullmann’s international experience includes development of a nationwide prepaid health plan in Mexico (MediPlan), owner and operator of world-renowned Warm Mineral Springs, and CEO of wellness company Bienestar, Inc.. Mr. Ullmann's public sector experience includes serving as a mental health director and county legislator (age of 25). Mr. Ullmann is an outspoken leader and innovator in the health care industry and has received numerous recognitions, distinctions, and awards. In 1994, he was named Health Care Entrepreneur of the Year in Southern New England in the Entrepreneur of the Year national competition sponsored by Inc. Magazine. In 2007, Mr. Ullmann received the CHIP Visionary Award from Sarasota County, Florida. Mr. Ullmann holds a B.S. degree in Pharmacy from Albany College of Pharmacy and Health Sciences, an MPA degree from the Maxwell School of Citizenship and Public Affairs, Syracuse University, and was a National HMO Fellow at Georgetown Medical School, Washington, DC.